Welcome

- Audio for this event is available via ReadyTalk[®] Internet streaming.
- No telephone line is required.
- Computer speakers or headphones are necessary to listen to streaming audio.
- Limited dial-in lines are available.
 Please send a chat message if needed.
- This event is being recorded.



Troubleshooting Audio


- Audio from computer speakers breaking up?
- Audio suddenly stop?
- Click the <u>Refresh</u> icon
 or
 Click F5






Troubleshooting Echo

- Hear a bad echo on the call?
- Echo is caused by multiple browsers/tabs open to a single event (multiple audio feeds).
- Close all but one browser/tab and the echo will clear.



Example of Two Browsers/Tabs Open in Same Event

Submitting Questions



09/27/2018



PCHQR Program Measure Overview: Admissions and Emergency Department (ED) Visits for Patients Receiving Chemotherapy (PCH-30 and PCH-31)

October 25, 2018

Speakers

Mario Marchesi, MPA Candidate

Chemotherapy Measure Lead Mathematica Policy Research (MPR)

Jessica Ross, MPH

Chemotherapy Measure Lead, MPR

Moderator

Lisa Vinson, BS, BSN, RN
PPS-Exempt Cancer Hospital (PCHQR) Program Lead

Hospital Inpatient Value, Incentives, and Quality Reporting
Outreach and Education Support Contractor

Acronyms and Abbreviations

CAUTI	Catheter-Associated Urinary Tract	HAI	Healthcare-Associated Infection
	Infection	IPPS	Inpatient Prospective Payment System
CDC	Centers for Disease Control and	LTCH	Long-Term Care Hospital
	Prevention	MPR	Mathematica Policy Research
CDI	Clostridium difficile Infection	MRSA	Methicillin-Resistant Staphylococcus
CLABSI	Central Line-Associated		aureus
	Bloodstream Infection	OCM	Oncology Care Measure
CMS	Centers for Medicare & Medicaid	OP	Outpatient
	Services	PCH	PPS-Exempt Cancer Hospital
CST	Cancer-Specific Treatment	PCHQR	PPS-Exempt Cancer Hospital Quality
DACA	Data Accuracy and Completeness		Reporting
	Acknowledgement	PPS	Prospective Payment System
EBRT	External Beam Radiotherapy	Q	Quarter
ED	Emergency Department	Q&A	Questions and Answers
FFS	Fee for Service	RSAR	Risk-Standardized Admission Rate
FSR	Facility-Specific Report	RSEDR	Risk-Standardized ED Visit Rate
FY	Fiscal Year	SSI	Surgical Site Infection
HCAHPS	Hospital Consumer Assessment of		-

10/25/2018 Back

Healthcare Providers and Systems

Purpose

This presentation will provide a review of the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure for the PCHQR Program.

This review will include:

- An overview of how the measure is specified and calculated
- An overview of the upcoming confidential reporting of the measure via FSRs
- Information on how to interpret measure results

Objectives

Upon completion of this program, participants will be able to:

- Understand how the chemotherapy measure is specified and calculated in the PCHQR Program
- Provide information on how to interpret measure results for the upcoming confidential reporting of the measure in the PCHQR Program via FSRs
- Answer questions related to the measure calculation and confidential reporting

Measure Background

The Admissions and ED Visits for Patients Receiving Outpatient Chemotherapy measure:

- Was adopted in the <u>FY 2017 IPPS/LTCH PPS Final</u> <u>Rule</u> (81 FR 57184 through 57191)
- Became effective for the FY 2019 program and subsequent years
 - Began with data from July 1, 2016 through June 30, 2017, and then will use data from July 1 through June 30 for subsequent years.

Measure Background (Cont.)

- Aims to assess care provided to cancer patients and encourage quality improvement efforts
 - Reduce the number of unplanned inpatient admissions and ED visits among cancer patients receiving chemotherapy in a PCH outpatient setting
- Addresses two National Quality Strategy priorities
 - Promoting effective communication and coordination of care
 - Promoting the most effective prevention and treatment practices for the leading causes of mortality

Back to the Basics

The OP Chemotherapy measure (PCH-30 and PCH-31)

- Is a risk-standardized outcome measure for patients 18 years or older who are receiving PCH-based outpatient chemotherapy treatment for all cancer types, except for leukemia
- Will utilize one year of Medicare FFS Part A and B administrative claims data
- Requires that the qualifying diagnosis on the admission or ED visit claim be the primary diagnosis or a secondary diagnosis accompanied by a primary diagnosis of cancer
- Has a window for identifying events limited to 30 days after PCH outpatient chemotherapy treatment encounters
- Identifies outcomes separately for the inpatient and ED measures
 - A patient can only qualify once for one of the two outcomes in each measurement period. If a patient experiences both outcomes, the measure counts toward the inpatient admission.

Overview of Presentation

- Summary of the Admissions and Emergency
 Department Visits for Patients Receiving Outpatient
 Chemotherapy measure ("chemotherapy measure")
- Measure specification, calculation, and rate standardization
- Upcoming confidential reporting of the measure via FSRs
- Interpreting measure results
- Questions related to the measure calculation and confidential reporting

Chemotherapy (PCH-30/31) Measure

- The goal of the chemotherapy measure is to improve the quality of care delivered to patients undergoing chemotherapy in a hospital outpatient setting.
- CMS will confidentially report results for the chemotherapy measure to facilities in October 2018.
 - Facilities do not have any additional data-collection requirements for this measure.
 - CMS will calculate the measure using Medicare claims data for chemotherapy treatments performed from July 1, 2016–June 30, 2017.
- The next confidential reporting of results for the chemotherapy measure to facilities is scheduled for spring 2019 using Medicare claims data for chemotherapy treatments performed from July 1, 2017–June 30, 2018.
- All facilities currently in the PCHQR Program with patients who received qualifying chemotherapy treatments will be included in the measure.

Measure Specification

Inclusion Criteria	Exclusion Criteria
Medicare FFS patients age 18+ at the start of the performance period	Patients with a diagnosis of leukemia at any time during the performance period
Patients with a diagnosis of cancer during the performance period	Patients who were not enrolled in 12 months of continuous in Medicare FFS Parts A and B prior to the first chemotherapy treatment during performance period
Patients who receive outpatient chemotherapy treatments at hospital outpatient departments	Patients who were not continuously enrolled in Medicare FFS Parts A and B in the 30 days after any chemotherapy treatment during the performance period

Measure Calculation

Measure outcome

- Inpatient admission: One or more inpatient hospital admissions for anemia, dehydration, diarrhea, emesis, fever, nausea, neutropenia, pain, pneumonia, or sepsis within 30 days of chemotherapy treatment
- ED visit: One or more ED visits for any of the same 10 diagnoses within 30 days of chemotherapy treatment, and no qualifying inpatient admissions

Risk-adjustment models

- Inpatient admission: Adjusts for 20 patient-level variables related to age, exposure, comorbidities, and cancer diagnosis categories
- **ED visit:** Adjusts for 15 patient-level variables related to age, exposure, comorbidities, and cancer diagnosis categories

Rate calculated

- Inpatient admission: Risk-standardized admission rate (RSAR)
- ED visit: Risk-standardized ED visit rate (RSEDR)

Risk-Standardization

 Equation for risk-standardized hospital visit rate calculation:

Rate =
$$\frac{\text{Predicted Outcomes}}{\text{Expected Outcomes}} \times \text{National Observed Rate}$$


 The best source of information on the risk-adjustment model is the methodology technical report posted at www.qualitynet.org > PPS-Exempt Cancer Hospitals > Measures > Chemotherapy Measure > Measure Methodology.

Facility-Specific Reports

- FSRs allow facilities to preview measure results and patient data prior to public reporting.
- In October 2018 CMS will provide facilities with FSRs based on chemotherapy treatments performed during July 1, 2016–June 30, 2017.
- FSRs include the following:
 - Measure performance results
 - National results (based on the performance at 11 PCHs only)
 - Detailed patient-level data used to calculate measure results
 - Summary of each facility's patient mix

Interpreting Measure Results


CMS categorizes each facility's performance separately for the RSAR and RSEDR by comparing each facility's 95% interval estimate with the national observed hospital visit rate.



Interpreting Measure Results (Cont.)


CMS assigns the performance categories as follows:

- "Worse than national rate"
 The entire 95% interval estimate of the facility's rate is higher than the national observed hospital visit rate.
- "No different from the national rate"
 The 95% interval estimate of the facility's rate includes the national observed hospital visit rate.
- "Better than national rate"
 The entire 95% interval estimate of the facility's rate is lower than the national observed hospital visit rate.



Interpreting Measure Results (Cont.)

Although CMS provides information to facilities on performance categories, the measure results will **not** be publicly reported during the January 2019 or July 2019 *Hospital Compare* releases.



Resources

Additional resources on the chemotherapy measure, including a measure fact sheet, frequently asked questions document, measure methodology information, and an FSR User Guide can be found on the Chemotherapy Measure PCHQR *QualityNet* page:

<u>www.qualitynet.org</u> > PPS-Exempt Cancer Hospitals > Measures > Chemotherapy Measure > Measure Methodology

Please direct questions about the measure to the *QualityNet* Questions and Answers (Q&A) tool here:

https://cms-ip.custhelp.com

PCHQR Program Measure Overview:
Admissions and Emergency Department (ED) Visits for Patients
Receiving Outpatient Chemotherapy (PCH-30 and PCH-31)

Key Dates and Reminders

Important Upcoming Dates

- Upcoming Outreach and Education Events*
 - o November 29, 2018
 - o December 19, 2018
- Upcoming Data Submissions
 - November 15, 2018
 - Q3 2017 CST hormone data
 - Q2 2018 HAI data
 - ❖ CAUTI, CLABSI, SSI, MRSA, CDI
 - January 3, 2019
 - Q3 2018 HCAHPS Survey data

^{*}Dates are tentative and subject to change.

Hospital Compare Key Dates

October 2018


- o Contains:
 - Q3 2016 through Q2 2017 CST chemo data
 - Q1 2016 through Q4 2016 CST hormone data
 - Q1 2017 through Q4 2017 HCAHPS Survey data
- Anticipated refresh October 31, 2018

January 2019

- Contains:
 - Q4 2016 through Q3 2017 CST chemo data
 - Q2 2016 through Q1 2017 CST hormone data
 - Q2 2017 through Q1 2018 HCAHPS Survey data
 - Q1 2017 through Q4 2017 OCM data
 - Q1 2017 through Q4 2017 EBRT data
- Tentative preview period November 17 through December 16, 2018
- Anticipated refresh January 30, 2019

Accessing the *QualityNet* **Questions and Answers Tool**

QualityNet Q&A Tool




10/25/2018 Acronyms

26

Selecting a Program Topic



Selecting an Answer Category



PCHQR Program Measure Overview:
Admissions and Emergency Department (ED) Visits for Patients
Receiving Outpatient Chemotherapy (PCH-30 and PCH-31)

Questions

PCHQR Program Measure Overview:
Admissions and Emergency Department (ED) Visits for Patients
Receiving Outpatient Chemotherapy (PCH-30 and PCH-31)

Closing Remarks

Disclaimer

This presentation was current at the time of publication and/or upload onto the *Quality Reporting Center* and *QualityNet* websites. Medicare policy changes frequently. Any links to Medicare online source documents are for reference use only. In the case that Medicare policy, requirements, or guidance related to this presentation change following the date of posting, this presentation will not necessarily reflect those changes; given that it will remain as an archived copy, it will not be updated.

This presentation was prepared as a service to the public and is not intended to grant rights or impose obligations. Any references or links to statutes, regulations, and/or other policy materials included in the presentation are provided as summary information. No material contained therein is intended to take the place of either written laws or regulations. In the event of any conflict between the information provided by the presentation and any information included in any Medicare rules and/or regulations, the rules and regulations shall govern. The specific statutes, regulations, and other interpretive materials should be reviewed independently for a full and accurate statement of their contents.